DECLARE-TIMI 58
Also written as: DECLARE-TIMI 58 — Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58
Large cardiovascular outcomes trial that demonstrated cardiovascular safety of dapagliflozin in patients with type 2 diabetes.
Full Definition
DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58) was a landmark randomized controlled trial involving over 17,000 patients with type 2 diabetes. The study demonstrated that dapagliflozin, an SGLT2 inhibitor, was non-inferior to placebo for major adverse cardiovascular events and showed benefits for hospitalization for heart failure. This trial was pivotal in establishing the cardiovascular safety profile of SGLT2 inhibitors in diabetes management.
Usage
Usage note: Often abbreviated as simply 'DECLARE trial' in clinical contexts.
In Context
- "The DECLARE-TIMI 58 results influenced updated clinical guidelines for diabetes management in patients with cardiovascular disease." — Clinical practice guideline
- "Following DECLARE-TIMI 58, cardiologists increasingly considered SGLT2 inhibitors for heart failure prevention in diabetic patients." — Medical journal article